Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: A report of 6 cases

Chinese-German Journal of Clinical Oncology

Volumn 9, Issue 9, 2010, Pages 502-506

  Wang, Fang ^a   Xia, Liangping ^a   Guo, Guifang ^a   Qiu, Huijuan ^a   Zhou, Feifei ^a   Zhang, Bei ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

cetuximab; efficacy; non first line; non small cell lung cancer (NSCLC); safety

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CIMETIDINE; CISPLATIN; DIPHENHYDRAMINE; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NORVILBINE; PACLITAXEL; PEMETREXED; UNCLASSIFIED DRUG;

ACNE; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHINA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HYPOMAGNESEMIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

EID: 77958195022     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-010-0632-3     Document Type: Article

References (25)

1. R. Rosell T. Moran C. Queralt, et al. 2009 Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 958 967 1:CAS:528:DC%2BD1MXhtVOqsL7M 10.1056/NEJMoa0904554 19692684
2. T.S. Mok Y.L. Wu S. Thongprasert, et al. 2009 Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957 1:CAS:528:DC%2BD1MXhtVygsbfK 10.1056/NEJMoa0810699 19692680
3. F.A. Shepherd J. Rodrigues Pereira T. Ciuleanu, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 1:CAS:528:DC%2BD2MXmtFaksbo%3D 10.1056/NEJMoa050753 16014882 (Pubitemid 41058344)
4. A. Chang P. Parikh S. Thongprasert, et al. 2006 Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study J Thorac Oncol 1 847 855 10.1097/01243894-200610000-00014 17409969 (Pubitemid 47181391)
5. Cappuzzo, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. ECCO ESMO, 2009.
6. T. Hida I. Okamoto T. Kashii, et al. 2008 Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG) J Clin Oncol 26 427s
7. R. Pirker J.R. Pereira A. Szczesna, et al. 2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 1525 1531 1:CAS:528: DC%2BD1MXltlaqurs%3D 10.1016/S0140-6736(09)60569-9 19410716
8. M.A. Socinski M.N. Saleh D.F. Trent, et al. 2009 A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC) Ann Oncol 20 1068 1073 1:STN:280: DC%2BD1MzmtlKitA%3D%3D 10.1093/annonc/mdn745 19188136
9. C.P. Belani M.T. Schreeder R.G. Steis, et al. 2008 Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study Cancer 113 2512 2517 1:CAS:528:DC%2BD1cXhtlKru77E 10.1002/cncr.23902 18816622
10. C.A. Butts D. Bodkin E.L. Middleman, et al. 2007 Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer J Clin Oncol 25 5777 5784 1:CAS:528: DC%2BD1cXnsFOgsg%3D%3D 10.1200/JCO.2007.13.0856 18089875
11. F. Robert G. Blumenschein R.S. Herbst, et al. 2005 Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer J Clin Oncol 23 9089 9096 1:CAS:528:DC%2BD28Xnt1ygtg%3D%3D 10.1200/JCO.2004.00.1438 16301597 (Pubitemid 46264008)
12. C.D. Thienelt P.A. Bunn Jr N. Hanna, et al. 2005 Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer J Clin Oncol 23 8786 8793 10.1200/JCO.2005.03.1997 16246975 (Pubitemid 46211524)
13. T.J. Lynch T. Patel L. Dreisbach, et al. 2010 Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 911 917 1:CAS:528:DC%2BC3cXktF2lsbk%3D 10.1200/JCO.2009.21.9618 20100966
14. Thatcher N, Linchy TJ, Butts CA, et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trails. WCLC 2009, oral presentation (abstract A3.7).
15. Lin H, Jiang J, Liang X, et al. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer, 2010 Feb 9 [Epub ahead of print].
16. L.P. Xia Y.M. Rong G.F. Guo, et al. 2010 The summary of efficacy of cetuximab combination with chemotherapy in NSCLC first-line setting: based on publication Chinese-German J Clin Oncol 9 137 141 1:CAS:528:DC%2BC3cXjs1arsb0%3D 10.1007/s10330-009-0194-4
17. E.S. Kim A.M. Mauer W.N. William Jr, et al. 2009 A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer Cancer 115 1713 1722 1:CAS:528:DC%2BD1MXltVOntbk%3D 10.1002/cncr.24148 19208430
18. N. Hanna R. Lilenbaum R. Ansari, et al. 2006 Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer J Clin Oncol 24 5253 5258 1:CAS:528:DC%2BD28XhtlemurbK 10.1200/JCO.2006.08.2263 17114658 (Pubitemid 46631370)
19. G.V. Scagliotti P. Parikh J. von Pawel, et al. 2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543 3551 1:CAS:528:DC%2BD1cXpvVWmtLg%3D 10.1200/JCO.2007.15.0375 18506025
20. A. Sandler R. Gray M.C. Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 1:CAS:528:DC%2BD28XhtlWqsbzI 10.1056/NEJMoa061884 17167137 (Pubitemid 44917502)
21. M. Reck J. von Pawel P. Zatloukal, et al. 2009 Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 1227 1234 1:CAS:528:DC%2BD1MXktFKhsL0%3D 10.1200/JCO.2007.14.5466 19188680
22. F.A. Shepherd J. Dancey R. Ramlau, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 1:CAS:528:DC%2BD3cXktVyjsLc%3D 10811675 (Pubitemid 30324363)
23. N. Hanna F.A. Shepherd F.V. Fossella, et al. 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 1:CAS:528:DC%2BD2cXpsVWmurk%3D 10.1200/JCO.2004.08.163 15117980 (Pubitemid 41079796)
24. E.F. Smit S.A. Burgers B. Biesma, et al. 2009 Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer J Clin Oncol 27 2038 2045 1:CAS:528:DC%2BD1MXls1CgtLY%3D 10.1200/JCO.2008.19.1650 19307503
25. Y.F. Zhang Z.W. Chen S. Lu 2009 Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer Chin Med J (Engl) 122 2472 2476 1:CAS:528:DC%2BD1MXhsVWgsb3O